Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement
- 1 August 1998
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 352 (9127) , 515-521
- https://doi.org/10.1016/s0140-6736(98)01350-6
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.Journal of Clinical Oncology, 1997
- High-Dose Chemotherapy for Breast CancerAnnals of Internal Medicine, 1996
- Breast cancer studies in the NetherlandsThe Lancet, 1996
- The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysisEuropean Journal Of Cancer, 1996
- Efficacy of up-front 5-fluorouracil – epidoxorubicin – cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patientsBritish Journal of Cancer, 1996
- The prognostic significance of the axillary apex biopsy in clinically operable breast cancerEuropean Journal Of Cancer, 1995
- Women Flock to ABMT for Breast Cancer Without Final ProofJNCI Journal of the National Cancer Institute, 1995
- High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.Journal of Clinical Oncology, 1993
- Evaluation of the prognostic value of triple node biopsy in early breast cancerBritish Journal of Surgery, 1990
- Subclavicular biopsy as a guideline for the treatment of breast cancerWorld Journal of Surgery, 1977